Dana-Farber Cancer Institute (DFCI) is world-renowned for its leadership in adult and pediatric cancer treatment and research. A Comprehensive Cancer Center, Dana-Farber is a pioneer in cancer care and research. DFCI is a world leader in basic and clinical research, training, and application of advanced diagnostic and treatment methods relating to cancer. The National Cancer Institute named DFCI as one of the country’s seven original comprehensive cancer centers in 1973. Today, DFCI is the administrative home for the Dana-Farber/Harvard Cancer Center (DF/HCC), one of more than forty-five NCI designated comprehensive cancer centers. DFCI employs over 4,500 people supporting more than 450,000 patient visits a year, is involved in some 900 clinical trials, and is internationally renowned for its blending of research and clinical excellence. DFCI’s expertise in these two aspects of the fight against cancer uniquely positions it to develop and test the next generation of cancer therapies in both the laboratory and the clinic.
DFCI is a principal teaching affiliate of Harvard Medical School, a federally designated Center for AIDS Research, and a founding member of the Dana-Farber/Harvard Cancer Center. Providing advanced training in cancer treatment and research for an international faculty, the Institute conducts community-based programs in cancer prevention, detection, and control throughout New England, and maintains joint programs with other Boston institutions affiliated with Harvard Medical School and the Partners Health Care System, including Brigham and Women’s Hospital, Boston Children’s Hospital, and Massachusetts General Hospital.
The Office for Human Research Studies (OHRS) functions as the central office for managing the ethical and scientific review and approval of all cancer-related clinical research protocols conducted by Dana-Farber/Harvard Cancer Center (DF/HCC), with specific responsibilities for supporting the Institutional Review Board and the Protocol Review and Monitoring System.
DFCI is seeking a Director of OHRS who is highly experienced, strategic and a well-respected leader with in-depth knowledge of the numerous issues impacting the review, approval and oversight of clinical and non-clinical research involving human subjects. The Director of OHRS provides leadership to staff, and works in close collaboration with other offices in the management, integration and improvement of the key processes that support clinical oncology research. The Director of OHRS works closely with senior clinical trials officials (e.g., clinical trials office, IRB office) and faculty of all of the institutions that participate in the Dana-Farber/Harvard Cancer Center (DF/HCC) consortium (see below for more detail) to ensure efficient, responsive and collaborative operations.
Please send confidential resumes, inquiries and referrals to:
Dana-Farber Cancer Institute